Nomura Holdings’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.88M | Sell |
209,400
-320,600
| -60% | -$8.54M | 0.02% | 593 |
|
|
2025
Q4 | $13.2M | Buy |
530,000
+300,000
| +130% | +$7.57M | 0.02% | 434 |
|
|
2025
Q3 | $5.86M | Buy |
230,000
+150,000
| +188% | +$3.7M | 0.01% | 705 |
|
|
2025
Q2 | $1.94M | Sell |
80,000
-769,500
| -91% | -$17.9M | ﹤0.01% | 845 |
|
|
2025
Q1 | $21.5M | Buy |
849,500
+664,500
| +359% | +$17.4M | 0.04% | 274 |
|
|
2024
Q4 | $4.91M | Sell |
185,000
-30,000
| -14% | -$814K | 0.01% | 768 |
|
|
2024
Q3 | $6.22M | Buy |
215,000
+125,000
| +139% | +$3.65M | 0.01% | 578 |
|
|
2024
Q2 | $2.52M | Sell |
90,000
-150,000
| -63% | -$4.13M | ﹤0.01% | 869 |
|
|
2024
Q1 | $6.66M | Sell |
240,000
-386,900
| -62% | -$10.7M | 0.02% | 558 |
|
|
2023
Q4 | $18M | Sell |
626,900
-160,300
| -20% | -$4.85M | 0.05% | 296 |
|
|
2023
Q3 | $26.1M | Sell |
787,200
-858,600
| -52% | -$30.4M | 0.07% | 178 |
|
|
2023
Q2 | $60.4M | Buy |
1,645,800
+1,555,800
| +1,729% | +$60.6M | 0.16% | 102 |
|
|
2023
Q1 | $3.67M | Sell |
90,000
-814,500
| -90% | -$35.2M | 0.01% | 655 |
|
|
2022
Q4 | $46.2M | Buy |
904,500
+900,000
| +20,000% | +$43.1M | 0.19% | 113 |
|
|
2022
Q3 | $200K | Hold |
4,500
| – | – | ﹤0.01% | 1251 |
|
|
2022
Q2 | $233K | Sell |
4,500
-10,000
| -69% | -$510K | ﹤0.01% | 1257 |
|
|
2022
Q1 | $751K | Sell |
14,500
-2,900
| -17% | -$150K | ﹤0.01% | 1193 |
|
|
2021
Q4 | $1.02M | Buy |
+17,400
| New | +$862K | ﹤0.01% | 1206 |
|
|
2020
Q2 | – | Sell |
-105,400
| Closed | -$3.24M | – | 1236 |
|
|
2020
Q1 | $3.24M | Sell |
105,400
-52,700
| -33% | -$1.8M | 0.01% | 385 |
|
|
2019
Q4 | $5.85M | Buy |
+158,100
| New | +$5.63M | 0.02% | 412 |
|
|
2018
Q1 | – | Sell |
-1,030,496
| Closed | -$35.2M | – | 1626 |
|
|
2017
Q4 | $35.2M | Sell |
1,030,496
-94,860
| -8% | -$3.23M | 0.06% | 185 |
|
|
2017
Q3 | $38.1M | Sell |
1,125,356
-105,400
| -9% | -$3.39M | 0.08% | 145 |
|
|
2017
Q2 | $39M | Sell |
1,230,756
-368,900
| -23% | -$11.6M | 0.1% | 125 |
|
|
2017
Q1 | $51.9M | Sell |
1,599,656
-8,951,516
| -85% | -$282M | 0.13% | 72 |
|
|
2016
Q4 | $326M | Sell |
10,551,172
-1,633,700
| -13% | -$49.9M | 0.83% | 15 |
|
|
2016
Q3 | $391M | Sell |
12,184,872
-656,432
| -5% | -$21.9M | 1.1% | 12 |
|
|
2016
Q2 | $425M | Sell |
12,841,304
-1,839,651
| -13% | -$58.7M | 1.39% | 9 |
|
|
2016
Q1 | $415M | Buy |
14,680,955
+10,920,705
| +290% | +$312M | 1.4% | 8 |
|
|
2015
Q4 | $115M | Buy |
3,760,250
+3,549,450
| +1,684% | +$112M | 0.32% | 37 |
|
|
2015
Q3 | $6.29M | Sell |
210,800
-274,040
| -57% | -$8.79M | 0.02% | 330 |
|
|
2015
Q2 | $15.4M | Sell |
484,840
-42,160
| -8% | -$1.37M | 0.04% | 183 |
|
|
2015
Q1 | $17.2M | Buy |
527,000
+308,400
| +141% | +$9.8M | 0.06% | 168 |
|
|
2014
Q4 | $6.45M | Sell |
218,600
-210,905
| -49% | -$6.05M | 0.02% | 510 |
|
|
2014
Q3 | $12.1M | Buy |
429,505
+376,805
| +715% | +$10.6M | 0.03% | 378 |
|
|
2014
Q2 | $1.48M | Sell |
52,700
-66,824
| -56% | -$1.9M | ﹤0.01% | 1277 |
|
|
2014
Q1 | $3.63M | Buy |
+119,524
| New | +$3.56M | ﹤0.01% | 884 |
|
Other funds holding PFE
VCM
VPM
Nomura Holdings's PFE Position: Q1 2026 in Review
Nomura Holdings reduced its Pfizer (PFE) stake by 49% in Q1 2026, selling an estimated $4.11M and leaving 157,700 shares worth $4.43M. The position accounts for 0.01% of the portfolio, ranked #679.
Nomura Holdings first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $61.3M in Q3 2017. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Nomura Holdings held 157,700 shares of Pfizer worth $4.43M as of Q1 2026.
- Nomura Holdings sold 154,473 Pfizer shares in Q1 2026, an estimated $4.11M.
- Pfizer made up 0.01% of Nomura Holdings's portfolio in Q1 2026, its #679 holding.
- Nomura Holdings first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Nomura Holdings's Pfizer position peaked at $61.3M in Q3 2017.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.